ATE153860T1 - Polymere und ihre verwendung als kontrastmittel bei der bilderzeugung mit magnetischer resonanz - Google Patents

Polymere und ihre verwendung als kontrastmittel bei der bilderzeugung mit magnetischer resonanz

Info

Publication number
ATE153860T1
ATE153860T1 AT91908011T AT91908011T ATE153860T1 AT E153860 T1 ATE153860 T1 AT E153860T1 AT 91908011 T AT91908011 T AT 91908011T AT 91908011 T AT91908011 T AT 91908011T AT E153860 T1 ATE153860 T1 AT E153860T1
Authority
AT
Austria
Prior art keywords
magnetic resonance
resonance imaging
polymers
contrast agents
polymer
Prior art date
Application number
AT91908011T
Other languages
English (en)
Inventor
Evan C Unger
Original Assignee
Imarx Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imarx Pharmaceutical Corp filed Critical Imarx Pharmaceutical Corp
Application granted granted Critical
Publication of ATE153860T1 publication Critical patent/ATE153860T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1803—Semi-solid preparations, e.g. ointments, gels, hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Signal Processing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Graft Or Block Polymers (AREA)
AT91908011T 1990-04-10 1991-04-09 Polymere und ihre verwendung als kontrastmittel bei der bilderzeugung mit magnetischer resonanz ATE153860T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50712590A 1990-04-10 1990-04-10

Publications (1)

Publication Number Publication Date
ATE153860T1 true ATE153860T1 (de) 1997-06-15

Family

ID=24017359

Family Applications (2)

Application Number Title Priority Date Filing Date
AT91908011T ATE153860T1 (de) 1990-04-10 1991-04-09 Polymere und ihre verwendung als kontrastmittel bei der bilderzeugung mit magnetischer resonanz
AT95111117T ATE185489T1 (de) 1990-04-10 1991-04-09 Polymere als kontrastmittel bei magnetischer resonanz

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT95111117T ATE185489T1 (de) 1990-04-10 1991-04-09 Polymere als kontrastmittel bei magnetischer resonanz

Country Status (8)

Country Link
EP (2) EP0526503B1 (de)
JP (1) JPH05506227A (de)
AT (2) ATE153860T1 (de)
DE (2) DE69126429T2 (de)
DK (1) DK0526503T3 (de)
ES (2) ES2103809T3 (de)
GR (1) GR3023806T3 (de)
WO (1) WO1991015753A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
US5948387A (en) * 1990-06-01 1999-09-07 Imarx Pharmaceutical Corp. Contrast media for ultrasonic imaging
US5420176A (en) * 1990-06-01 1995-05-30 Imarx Pharmaceutical Corp. Contrast media for ultrasonic imaging
AU650466B2 (en) * 1990-06-01 1994-06-23 Evan C. Unger Contrast media for ultrasonic imaging
DE4117782C2 (de) * 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel
JPH07501331A (ja) * 1991-11-19 1995-02-09 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 改良された診断用の造影のためのゲル粒子造影剤
US5514379A (en) * 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5323780A (en) * 1992-08-07 1994-06-28 University Of Florida Research Foundation, Inc. Artifact-free imaging contrast agent
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
ES2199226T3 (es) * 1992-09-04 2004-02-16 The General Hospital Corporation Polimeros biocompatibles que contienen mitades diagnosticas o terapeuticas.
JPH08502300A (ja) * 1992-10-14 1996-03-12 スターリング ウィンスロップ アイエヌシー． 治療および診断像形成組成物および方法
WO1994009056A1 (en) * 1992-10-14 1994-04-28 Sterling Winthrop Inc. Chelating polymers
US5817292A (en) * 1992-10-14 1998-10-06 Nycomed Imaging As MR imaging compositions and methods
US5756688A (en) * 1992-10-14 1998-05-26 Sterling Winthrop Inc. MR imaging compositions and methods
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
DE69421943T2 (de) 1994-09-27 2000-05-18 Nycomed Imaging As, Oslo Kontrastmittel
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
WO1999052564A1 (en) * 1998-04-09 1999-10-21 Nycomed Imaging A.S Method
DE19942278C2 (de) * 1999-09-04 2001-09-13 Messer Griesheim Gmbh Quantitative Bestimmung des Xenongehaltes in Flüssigkeiten mit Hilfe der NMR-Spektroskopie
DE602006007177D1 (de) 2005-12-05 2009-07-16 Nitto Denko Corp Polyglutamat-aminosäure-konjugate und verfahren
EP2020244B1 (de) * 2006-05-17 2014-03-05 Otsuka Pharmaceutical Co., Ltd. Magnetresonanz-Kontrastmittel mit Polyethylenglykol und Magnetresonanz-Bild-Aufnahmeverfahren
EP2155255B1 (de) 2007-05-09 2013-08-14 Nitto Denko Corporation Zusammensetzungen, die eine hydrophobe Verbindung und ein Polyaminosäurekonjugat beinhalten
KR101303567B1 (ko) * 2011-03-08 2013-09-23 주식회사 인트론바이오테크놀로지 카르복실기가 도입된 만난으로 코팅된 자기공명영상 조영제 및 그것의 제조 방법
IL296875A (en) 2014-12-31 2022-12-01 Lantheus Medical Imaging Inc Fat-wrapped gas microsphere preparations and related methods
CN109641068B (zh) 2016-05-04 2022-09-30 蓝瑟斯医学影像公司 用于制备超声波造影剂的方法及装置
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069306A (en) * 1974-03-14 1978-01-17 Pharmacia Aktiebolag X-ray contrast preparation containing a hydrophilic polymer containing amino groups
US4775522A (en) * 1983-03-04 1988-10-04 Children's Hospital Research Foundation, A Division Of Children's Hospital Medical Center NMR compositions for indirectly detecting a dissolved gas in an animal
US4586511A (en) * 1983-03-04 1986-05-06 Children's Hospital Medical Center Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance
DE3316703A1 (de) * 1983-05-04 1984-11-08 Schering AG, 1000 Berlin und 4709 Bergkamen Orales kontrastmittel fuer die kernspintomographie und dessen herstellung
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
DE3577185D1 (de) * 1984-11-01 1990-05-23 Nycomed As Paramagnetische kontrastmittel fuer die anwendung in "in vivo" nmr-diagnostischen methoden und die herstellung davon.
US4849210A (en) * 1985-05-08 1989-07-18 Molecular Biosystems, Inc. Magnetic resonance imaging of liver and spleen with superparamagnetic contrast agents
JPS62153229A (ja) * 1985-12-27 1987-07-08 Nippon Oil Co Ltd 皮膚マ−カ−
US4871716A (en) * 1986-02-04 1989-10-03 University Of Florida Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and methods of preparation thereof
US4729892A (en) * 1986-03-21 1988-03-08 Ciba-Geigy Corporation Use of cross-linked hydrogel materials as image contrast agents in proton nuclear magnetic resonance tomography and tissue phantom kits containing such materials
US4933441A (en) * 1987-01-27 1990-06-12 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
US4838274A (en) * 1987-09-18 1989-06-13 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance imaging
GB8813425D0 (en) * 1988-06-07 1988-07-13 Hall L D Magnetic resonance imaging
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US4996041A (en) * 1988-08-19 1991-02-26 Toshiyuki Arai Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system
GB8916780D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions

Also Published As

Publication number Publication date
DK0526503T3 (da) 1997-10-27
WO1991015753A1 (en) 1991-10-17
DE69131721T2 (de) 2000-03-02
EP0693288A1 (de) 1996-01-24
ATE185489T1 (de) 1999-10-15
EP0526503A4 (en) 1993-02-24
EP0693288B1 (de) 1999-10-13
JPH05506227A (ja) 1993-09-16
EP0526503A1 (de) 1993-02-10
DE69126429T2 (de) 1997-10-23
GR3023806T3 (en) 1997-09-30
EP0526503B1 (de) 1997-06-04
ES2103809T3 (es) 1997-10-01
DE69126429D1 (de) 1997-07-10
ES2138122T3 (es) 2000-01-01
DE69131721D1 (de) 1999-11-18

Similar Documents

Publication Publication Date Title
ATE153860T1 (de) Polymere und ihre verwendung als kontrastmittel bei der bilderzeugung mit magnetischer resonanz
US5527521B1 (en) Low density microspheres and suspensions and their use as contrast agents for computed tomography and in other applications
DE69128422D1 (de) Kontrastmittel für ultraschallabbildung
DE69111596D1 (de) Verwendung von zwitterionen zur mobilisierung isoelektrisch fokussierter ampholytzonen.
DE69102451D1 (de) Herstellung und Verwendung von Farbstoffen.
DE69127235D1 (de) Biologisch verträgliche perforierte Membranen und ihre Verwendung als Kunsthaut
DE69011119D1 (de) Magnetkopf-aufhaengevorrichtung zur verwendung bei photographischen filmen.
DE69901433D1 (de) Homogene und stabile suspension ohne emulgiermittel,verfahren zu ihrer herstellung und ihre verwendung in nahrungsmittelzusammnensetzungen
DE58904699D1 (de) 1-olefin isoblockpolymer und verfahren zu seiner herstellung.
DE69007891D1 (de) 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one und -thione und ihre Verwendung bei der AIDS-Vorbeugung oder -Behandlung.
DE69013922D1 (de) Magnetkopf-aufhängevorrichtung zur verwendung bei fotografischen filmen.
DE68928610D1 (de) Passiver Ausgleichskörper zur Korrektur von (3,2)- und (3,-2)-harmonischen Gliedern bei magnetischen Resonanzmagneten
PT795605E (pt) Receptor de lipoproteina de baixa densidade desnaturada
DE69214718D1 (de) 4,4'-Biphenylendiphosphonit Verbindungen und ihre Verwendung
DE69830741D1 (de) Verflüssigte polymersuspensionen von kationischen polysacchariden in polyolen und ihre verwendung bei der herstellung von körperpflegemitteln
DE59108892D1 (de) Verfahren zur reinigung von cytokeratin 20 und dessen verwendung zur erzeugung von antikörpern
DE69202819D1 (de) Initiatorsuspensionen, ihre Herstellung und Verwendung.
IT9067588A0 (it) Apparecchiatura atta ad accertare e misurare le condizioni di efficienza fisica di utenti di autoveicoli e le capacita' di guida degli stessi con e senza l'ausilio di adattamenti e/o protesi.
DE69031606D1 (de) Kern-Schale-Polymer, Herstellung und dessen Verwendung
DE58908788D1 (de) Modifizierte Blockpolymerisate, ihre Herstellung und Verwendung.
DE59107953D1 (de) Verwendung von wässrigen Polymerisatdispersionen
DE59004374D1 (de) Neue Polymere und ihre Verwendung.
DE59005898D1 (de) Dinatriumsalz des Trimercapto-s-triazin-hexahydrats, Verfahren zu seiner Herstellung und Verwendung.
ATE256657T1 (de) 2,5-substituierte benzolsulfonylharnstoffe und - thioharnstoffe, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmzeutische präparate
DE69016085D1 (de) Serinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung in der Humantherapie.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee